Genetic approaches to metabolic bone diseases

被引:20
作者
Hannan, Fadil M. [1 ,2 ]
Newey, Paul J. [3 ]
Whyte, Michael P. [4 ,5 ]
Thakker, Rajesh V. [1 ]
机构
[1] Univ Oxford, Radcliffe Dept Med, Acad Endocrine Unit, Oxford, England
[2] Univ Liverpool, Inst Ageing & Chron Dis, Dept Musculoskeletal Biol, Liverpool, Merseyside, England
[3] Univ Dundee, Ninewells Hosp & Med Sch, Div Mol & Clin Med, Dundee, Scotland
[4] Shriners Hosp Children, Ctr Metab Bone Dis & Mol Res, St Louis, MO 63110 USA
[5] Washington Univ, Sch Med, Barnes Jewish Hosp, Div Bone & Mineral Dis,Dept Internal Med, St Louis, MO 63110 USA
基金
英国惠康基金;
关键词
genetic diseases; genetics and pharmacogenetics; molecular biology; osteoporosis; rheumatology; CALCIUM-SENSING RECEPTOR; HEREDITARY HYPOPHOSPHATEMIC RICKETS; MCCUNE-ALBRIGHT-SYNDROME; EARLY-ONSET OSTEOPOROSIS; CONCISE GUIDE; POSTMENOPAUSAL WOMEN; MOLECULAR DIAGNOSIS; SEQUENCE VARIANTS; WIDE ASSOCIATION; MINERAL DENSITY;
D O I
10.1111/bcp.13803
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Metabolic bone diseases comprise a diverse group of disorders characterized by alterations in skeletal homeostasis, and are often associated with abnormal circulating concentrations of calcium, phosphate or vitamin D metabolites. These diseases commonly have a genetic basis and represent either a monogenic disorder due to a germline or somatic single gene mutation, or an oligogenic or polygenic disorder that involves variants in more than one gene. Germline single gene mutations causing Mendelian diseases typically have a high penetrance, whereas the genetic variations causing oligogenic or polygenic disorders are each associated with smaller effects with additional contributions from environmental factors. Recognition of familial monogenic disorders is of clinical importance to facilitate timely investigations and management of the patient and any affected relatives. The diagnosis of monogenic metabolic bone disease requires careful clinical evaluation of the large diversity of symptoms and signs associated with these disorders. Thus, the clinician must pursue a systematic approach beginning with a detailed history and physical examination, followed by appropriate laboratory and skeletal imaging evaluations. Finally, the clinician must understand the increasing number and complexity of molecular genetic tests available to ensure their appropriate use and interpretation.
引用
收藏
页码:1147 / 1160
页数:14
相关论文
共 115 条
[1]   Clinical and molecular findings in osteoporosis-pseudoglioma syndrome [J].
Ai, MR ;
Heeger, S ;
Bartels, CF ;
Schelling, DK .
AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 77 (05) :741-753
[2]   THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Catalytic receptors [J].
Alexander, Stephen P. H. ;
Fabbro, Doriano ;
Kelly, Eamonn ;
Marrion, Neil V. ;
Peters, John A. ;
Faccenda, Elena ;
Harding, Simon D. ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
Southan, Christopher ;
Davies, Jamie A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 :S225-S271
[3]  
Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS272, DOI [10.1111/bph.13877, 10.1111/bph.13882]
[4]   THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Nuclear hormone receptors [J].
Alexander, Stephen P. H. ;
Cidlowski, John A. ;
Kelly, Eamonn ;
Marrion, Neil V. ;
Peters, John A. ;
Faccenda, Elena ;
Harding, Simon D. ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
Southan, Christopher ;
Davies, Jamie A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 :S208-S224
[5]   THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors [J].
Alexander, Stephen P. H. ;
Christopoulos, Arthur ;
Davenport, Anthony P. ;
Kelly, Eamonn ;
Marrion, Neil V. ;
Peters, John A. ;
Faccenda, Elena ;
Harding, Simon D. ;
Pawson, Adam J. ;
Sharman, Joanna L. ;
Southan, Christopher ;
Davies, Jamie A. .
BRITISH JOURNAL OF PHARMACOLOGY, 2017, 174 :S17-S129
[6]  
[Anonymous], GENETICS BONE BIOL S
[7]  
[Anonymous], MONTR CAN AM SOC BON
[8]  
[Anonymous], AM SOC BON MIN RES A
[9]  
[Anonymous], 1993, GeneReviews
[10]  
[Anonymous], 2000, ENDOTEXT